MedTrace Logo

Relative Bioavailability and Food Effect Study of CVN424

NCT05635461 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This is a Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension and Tablet Formulations in Healthy Volunteers Under Fasted and Fed Conditions.

Conditions

Interventions

DRUG

CVN424

150 mg of either tablet or suspension formulation

Sponsors & Collaborators

  • Cerevance Beta, Inc.

    lead INDUSTRY

Principal Investigators

  • Dr. Martin Bexon, MD · Cerevance Beta, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-09
Primary Completion
2022-11-11
Completion
2022-11-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05635461 on ClinicalTrials.gov